Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/151860
Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common inflammatory condition affecting the upper airways, with chronic symptoms such as nasal congestion, partial (hyposmia) or total (anosmia) loss of smell, anterior/posterior rhinorrhea, and mild facial pain.1 As many as 66% of patients with CRSwNP have comorbid asthma and suffer from more severe nasal obstruction, higher levels of lower airway inflammation, and worse asthma control than those without CRS.2, 3 Thus, patients with CRSwNP and comorbid asthma have a high disease burden, seriously impacting health-related quality of life (HRQoL).2, 3 Markers of type 2-mediated inflammation and antibody production (eg, IL-5, IgE) are associated with both CRSwNP and asthma pathogenesis.2
Citació
Citació
BACHERT, Claus, HELLINGS, Peter w., MULLOL I MIRET, Joaquim, NACLERIO, Robert m., CHAO, Jingdong, AMIN, Nikhil, GRABHER, Annette, SWANSON, Brian n., HAMILTON, Jennifer d., GUILLONNEAU, Sophie, Christine Taniou, ZHANG, Donghui, PIROZZI, Gianluca, GRAHAM, Neil m. h., STAUDINGER, Heribert, MANNENT, Leda p., KHAN, Asif. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. _The Journal of Allergy and Clinical Immunology: In Practice_. 2019. Vol. 7, núm. 7, pàgs. 2447-2449. [consulta: 5 de maig de 2026]. ISSN: 2213-2198. [Disponible a: https://hdl.handle.net/2445/151860]